Placement Agency Agreement Sample Contracts

Moleculin Biotech, Inc. – Placement Agency Agreement (June 21st, 2018)
Matinas BioPharma Holdings, Inc. – Matinas Biopharma Holdings, Inc. (A Delaware Corporation) 8,000 Shares of Series B Convertible Preferred Stock PLACEMENT AGENCY AGREEMENT (June 19th, 2018)
Greenpro Capital Corp. – PLACEMENT AGENCY AGREEMENT Between GREENPRO CAPITAL CORP. (A Nevada Corporation) and NETWORK 1 FINANCIAL SECURITIES, INC. As Placement Agent (June 6th, 2018)

This letter (this "Agreement") constitutes the agreement between Greenpro Capital Corp., a Nevada corporation (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of the Company, the "Company") and Network 1 Financial Securities, Inc. (the "Placement Agent") pursuant to which the Placement Agent shall serve as the Placement Agent (the "Services") for the Company, on a reasonable "best efforts" basis, in connection with the proposed offer (the "Offering") by the Company of its Securities (as defined in Section 3 of this Agreement).

PLACEMENT AGENCY AGREEMENT May 17, 2018 (May 22nd, 2018)
Cidara Therapeutics, Inc. PLACEMENT AGENCY AGREEMENT (May 21st, 2018)
Placement Agency Agreement (May 9th, 2018)

This letter (this "Agreement") constitutes the agreement between Pareteum Corp., a Delaware corporation (the "Company") and Dawson James Securities, Inc. ("Dawson" or the "Placement Agent") pursuant to which Dawson shall serve as the exclusive placement agent (the "Services") for the Company, on a reasonable "best efforts" basis, in connection with the proposed offer and placement (the "Offering") by the Company of its Securities (as defined Section 3 of this Agreement). The Company expressly acknowledges and agrees that Dawson's obligations hereunder are on a reasonable "best efforts" basis only and that the execution of this Agreement does not constitute a commitment by Dawson to purchase the Securities and does not ensure the successful placement of the Securities or any portion thereof or the success of Dawson placing the Securities.

Sysorex Global Holdings Corp. – Placement Agency Agreement (April 24th, 2018)
Oragenics, Inc. – PLACEMENT AGENCY AGREEMENT April 6, 2018 (April 10th, 2018)
Mirna Therapeutics, Inc. – SYNLOGIC, INC. (A Delaware Corporation) 3,280,000 Shares of Common Stock PLACEMENT AGENCY AGREEMENT (April 6th, 2018)
Placement Agency Agreement (April 3rd, 2018)
Medical Transcription Billing, Corp – Placement Agency Agreement (April 2nd, 2018)
2,222,222 Shares of Common Stock SPHERIX INCORPORATED PLACEMENT AGENCY AGREEMENT (March 19th, 2018)
Oculus Innovative Sciences – Placement Agency Agreement (March 6th, 2018)

This letter (this "Agreement") constitutes the agreement between Sonoma Pharmaceuticals, Inc., a Delaware corporation (the "Company") and Dawson James Securities, Inc. ("Dawson") pursuant to which Dawson shall serve as the lead placement agent, and with The Benchmark Company, LLC as co-placement agent for which Dawson is acting as representative (Dawson and The Benchmark Company, LLC being collectively called the "Placement Agent") (the "Services"), for the Company, on a reasonable "best efforts" basis, in connection with the proposed offer and placement (the "Offering") by the Company of its Securities (as defined Section 3 of this Agreement). The Company expressly acknowledges and agrees that Dawson's obligations hereunder are on a reasonable "best efforts" basis only and that the execution of this Agreement does not constitute a commitment by Dawson to purchase the Securities and does not ensure the successful placement of the Securities or any portion thereof or the success of Daws

Moleculin Biotech, Inc. – PLACEMENT AGENCY AGREEMENT February 16, 2018 (February 16th, 2018)
Sysorex Global Holdings Corp. – Placement Agency Agreement (February 16th, 2018)
Topspin Medical Inc – Placement Agency Agreement (February 1st, 2018)
Sysorex Global Holdings Corp. – Placement Agency Agreement (February 1st, 2018)
Placement Agency Agreement (January 24th, 2018)
Longfin Corp – PLACEMENT AGENCY AGREEMENT January 22, 2018 (January 23rd, 2018)
Delcath Systems – Placement Agency Agreement (January 17th, 2018)
Akoustis Technologies, Inc. – Placement Agency Agreement (January 16th, 2018)
Sysorex Global Holdings Corp. – Placement Agency Agreement (January 9th, 2018)
Motus GI Holdings, Inc. – Placement Agency Agreement (January 5th, 2018)
Topspin Medical Inc – PLACEMENT AGENCY AGREEMENT December __, 2017 (December 19th, 2017)
Topspin Medical Inc – PLACEMENT AGENCY AGREEMENT December __, 2017 (December 18th, 2017)
Placement Agency Agreement (December 12th, 2017)
Medical Transcription Billing, Corp – Placement Agency Agreement (December 11th, 2017)
Placement Agency Agreement (December 6th, 2017)

This letter (this "Agreement") constitutes the agreement between Biocept, Inc., a Delaware corporation (the "Company") and Dawson James Securities, Inc. ("Dawson" or the "Placement Agent") pursuant to which Dawson shall serve as the exclusive placement agent (the "Services") for the Company, on a reasonable "best efforts" basis, in connection with the proposed offer and placement (the "Offering") by the Company of its Securities (as defined Section 3 of this Agreement). The Company expressly acknowledges and agrees that Dawson's obligations hereunder are on a reasonable "best efforts" basis only and that the execution of this Agreement does not constitute a commitment by Dawson to purchase the Securities and does not ensure the successful placement of the Securities or any portion thereof or the success of Dawson placing the Securities.

THERMOGENESIS Corp. – Placement Agency Agreement (December 1st, 2017)

This letter (this "Agreement") constitutes the agreement between Cesca Therapeutics Inc., a Delaware corporation (the "Company"), and Dawson James Securities, Inc. ("Dawson" or the "Placement Agent") pursuant to which Dawson shall serve as the exclusive placement agent (the "Services") for the Company, on a reasonable "best efforts" basis, in connection with the proposed offer and placement (the "Offering") by the Company of its Securities (as defined Section 3 of this Agreement). The Company expressly acknowledges and agrees that Dawson's obligations hereunder are on a reasonable "best efforts" basis only and that the execution of this Agreement does not constitute a commitment by Dawson to purchase the Securities and does not ensure the successful placement of the Securities or any portion thereof or the success of Dawson in placing the Securities.

Placement Agency Agreement (December 1st, 2017)

This letter (this "Agreement") constitutes the agreement between Pareteum Corp., a Delaware corporation (the "Company") and Dawson James Securities, Inc. ("Dawson" or the "Placement Agent") pursuant to which Dawson shall serve as the exclusive placement agent (the "Services") for the Company, on a reasonable "best efforts" basis, in connection with the proposed offer and placement (the "Offering") by the Company of its Securities (as defined Section 3 of this Agreement). The Company expressly acknowledges and agrees that Dawson's obligations hereunder are on a reasonable "best efforts" basis only and that the execution of this Agreement does not constitute a commitment by Dawson to purchase the Securities and does not ensure the successful placement of the Securities or any portion thereof or the success of Dawson placing the Securities.

THERMOGENESIS Corp. – Placement Agency Agreement (November 29th, 2017)

This letter (this "Agreement") constitutes the agreement between Cesca Therapeutics Inc., a Delaware corporation (the "Company"), and Dawson James Securities, Inc. ("Dawson" or the "Placement Agent") pursuant to which Dawson shall serve as the exclusive placement agent (the "Services") for the Company, on a reasonable "best efforts" basis, in connection with the proposed offer and placement (the "Offering") by the Company of its Securities (as defined Section 3 of this Agreement). The Company expressly acknowledges and agrees that Dawson's obligations hereunder are on a reasonable "best efforts" basis only and that the execution of this Agreement does not constitute a commitment by Dawson to purchase the Securities and does not ensure the successful placement of the Securities or any portion thereof or the success of Dawson in placing the Securities.

Leap Therapeutics, Inc. – Placement Agency Agreement (November 17th, 2017)
Bio-Path Holdings Inc – Placement Agency Agreement (November 6th, 2017)
PLACEMENT AGENCY AGREEMENT November 2, 2017 (November 3rd, 2017)
Soligenix Inc. – Placement Agency Agreement (October 31st, 2017)

Introduction. Subject to the terms and conditions herein (this "Agreement"), Soligenix,, Inc., a Delaware corporation (the "Company"), hereby agrees to sell up to an aggregate of Nine Hundred Eighty Two Thousand (982,000) shares of common stock (the "Shares"), par value $0.001 per share (the "Common Stock"), (the Shares or the "Securities") directly to various investors (each, an "Investor" and, collectively, the "Investors") through Aegis Capital Corp. (the "Placement Agent" and, each, a "Placement Agent"), as placement agent. The Shares shall be offered and sold pursuant to Section 4(a)(2) under the Securities Act (as hereinafter defined). The documents executed and delivered by the Company and the Investors in connection with the Offering (as defined below), including, without limitation, a securities purchase agreement (the "Purchase Agreement"), shall be collectively referred to herein as the "Transaction Documents." The purchase price to the Investors for each Share is $2.00. The